Michael Partridge | Vertex Pharmaceuticals, Inc. |
Jeffrey M. Leiden | Vertex Pharmaceuticals, Inc. |
Ian F. Smith | Vertex Pharmaceuticals, Inc. |
Reshma Kewalramani | Vertex Pharmaceuticals, Inc. |
Stuart A. Arbuckle | Vertex Pharmaceuticals, Inc. |
Phil Nadeau | Cowen & Co. LLC |
Geoff Meacham | Barclays Capital, Inc. |
Michael J. Yee | Jefferies LLC |
Robyn Karnauskas | Citigroup Global Markets, Inc. |
Geoffrey C. Porges | Leerink Partners LLC |
Terence Flynn | Goldman Sachs & Co. LLC |
Eliana Merle | Cantor Fitzgerald Securities |
Ying Huang | Bank of America Merrill Lynch |
Brian Abrahams | RBC Capital Markets LLC |
Benjamin Burnett | Stifel, Nicolaus & Co., Inc. |
Cory W. Kasimov | JPMorgan Securities LLC |
Welcome to the Vertex third quarter 2018 conference call. This is Michael Partridge, Senior Vice President of Investor Relations for Vertex. Tonight, we will review our financial results, our continued progress to develop new medicines for all people with cystic fibrosis and recent advances in our research and development pipeline. Dr. Jeff Leiden, Chairman and CEO; and Ian Smith, Chief Operating Officer, will provide prepared remarks this evening.